FDA approves new treatment for Parkinson's

Newron Therapeutics on Thursday earned approval from the Food and Drug Administration for its drug Xadago.

Xadago is intended to be used as an add-on treatment for patients with Parkinson's disease who are already taking a combination therapy of levodopa and carbidopa for the condition, yet still experiencing "off" episodes.

"Off episodes" occur when a patient's medication is not working properly, resulting in heightened Parkinson's symptoms like tremors or difficulty walking, according to the FDA.

"Xadago as an add-on to levodopa/carbidopa provided a significant reduction in off time and a significant increase in ON time without troublesome dyskinesia in [Parkinson's] patients experiencing motor fluctuations," Warren Olanow, MD, a professor of neurology and neuroscience at the Mount Sinai School of Medicine in New York City, said in a statement.

More articles on supply chain:

96% of older Americans want Medicare to negotiate drug costs: 4 survey findings
FDA granted 99% of applications for access to unapproved drugs in FY 2016
FDA warns of safety risks with Abbott's dissolving stent: 5 takeaways

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars